Date: 2011-10-10
Type of information: R&D agreement
Compound: Alzheimer’s disease biomarkers
Company: Exonhit (France) Pfizer (USA - NY)
Therapeutic area: Neurodegenerative diseases
Type agreement: R&D
Action mechanism:
Disease: Alzheimer’s disease
Details: Exonhit has entered into a research agreement with Pfizer Inc. for the identification of new Alzheimer’s disease biomarkers using Exonhit’s Genome-Wide SpliceArray™ (GWSA) platform. As part of the agreement, the two companies will jointly conduct a pilot study using Exonhit’s GWSA platform to gain insight on Alzheimer’s disease molecular markers associated with clinical parameters. More specifically, the purpose of the research work is to seek to identify progression and other biomarkers that could segregate healthy elderly controls, patients with mild cognitive impairment (MCI) and patients with AD. Test samples for the study will be provided by Pfizer from a number of subjects in each of these three groups over a period of time.
Financial terms: Financial details were not disclosed.
Latest news:
